Trending Topics in Gastroenterology
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
What Did the Study Find? This large study compared 9 clinical risk scores in 853,131 adults with imaging-confirmed, noncirrhotic steatotic liver disease. Over 10 years, 3.96% developed cirrhosis...
What Did the Study Find? This large study compared 9 clinical risk scores in 853,131 adults with imaging-confirmed, noncirrhotic steatotic liver disease. Over 10 years, 3.96% developed cirrhosis...
What Did the Study Find? Investigators analyzed approximately 2,400 adults with biopsy-confirmed MASLD to characterize cirrhosis developing before age 50. About 25% of cirrhosis cases occurred before age...
What’s New? China has approved semaglutide 2.4 mg (Wegovy) for adults with non-cirrhotic MASH and F2–F3 fibrosis, making it the first GLP-1 receptor agonist specifically approved for MASH...
Introduction: With pharmacotherapy now available for selected patients with MASH, clinicians need practical guidance on who should be treated and how response should be monitored. This 40-expert international...
Introduction: FibroScan liver stiffness measurement (LSM) is widely used to stage fibrosis in MASLD, but its value as a dynamic prognostic marker is less established. This study examined...
Introduction: Saroglitazar, a PPAR-α/γ agonist already used for MASLD/MASH in India, is being developed internationally as a potential treatment for MASH with fibrosis. The global EVIDENCES-X trial evaluated...
Introduction: Diet is central to MASLD management, but whether one dietary pattern is superior remains uncertain. This 6-month randomized trial compared a Mediterranean diet, low-carbohydrate high-protein diet, and...
Introduction: MASLD affects a large proportion of Indian adults, but genetic drivers may differ by ancestry and may influence different stages of disease. This North Indian candidate-gene study...
Introduction: Accurate fibrosis assessment is central to risk stratification in MASLD, but commonly used non-invasive tests (NITs) often leave many patients in an indeterminate “grey zone.” This multicenter...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.